George C. Prendergast

George Prendergast, PhD, is the President and Chief Executive Officer of the Lankenau Institute for Medical Research (LIMR). He also holds the rank of Professor in the Department of Pathology, Anatomy, and Cell Biology at the Sidney Kimmel College of Medicine, Thomas Jefferson University. Before moving to LIMR he held positions as Senior Director of the Cancer Research Group at The DuPont Pharmaceutical Company and Associate Professor at The Wistar Institute. Dr. Prendergast and his colleagues pioneered the preclinical discovery and validation of indoximod and the first structural classes of true enzymatic small molecule inhibitors of IDO1, a therapeutic target now being explored worldwide in oncology clinical trials. Dr. Prendergast is a graduate of the University of Pennsylvania where he received his BA in Biochemistry. He received his MS in Molecular Biophysics and Biochemistry from Yale University and his Ph.D. in Molecular Biology from Princeton University. He served as the Editor-in-Chief of Cancer Research from 2010 – 2017 and is co-editor of the textbook, Cancer Immunology: Immune Suppression and Tumor Growth (2013; Academic Press, Waltham, MA).